Juvabis AG is a clinical stage biotech company developing the next generation of aminoglycoside antibiotics. Its first-in-class human therapeutic portfolio demonstrates preclinical safety and efficacy in critical systemic infections by highly drug-resistant Gram-negative pathogens and mycobacteria.